Takeda Pharmaceutical Co 株価情報 (NYSE: TAK)

最新ニュース Takeda Pharmaceutical Co (NYSE:TAK) 株価情報

Takeda Pharmaceutical Co

Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co Ltd

TransAKT Ltd

TAKIGAMI STEEL CONSTRCTN by Takigami Steel Construction Co. Ltd.

Takigami Steel Construction Co Ltd

TAKAMATSU CONSTRUCTION GR by TAKAMATSU CONSTRUCTION GROUP CO LTD

Takamatsu Construction Group Co Ltd

VOLATUS AEROSPACE INC by VOLATUS AEROSPACE INC.

Volatus Aerospace Inc

When it comes to personal finance, Kevin O&#8217;Leary isn&#8217;t sugarcoating anything. The &#8220;Shark Tank&#8221; investor is once again calling out high-interest <a href="https://www.benzinga.com/news/25/04/44889438/survey-unveils-american-misconceptions-about-credit-card-debt-management">credit card debt</a> and urging people to make getting out of it a top priority.
<h2 class="wp-block-heading">Debt Takes You Down</h2>
&#8220;The reason I own all the credit card companies is I&#8217;m getting paid 23% by people that have credit balances on their cards,&#8221; O&#8217;Leary said in a recent <a href="https://x.com/kevinolearytv/status/1927356996786786449">post on X</a>. &#8220;It&#8217;s crazy that you would pay interest of 23% on what you owe the credit card company.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The reason I own all the credit card companies is I&#39;m getting paid 23% by people that have credit balances on their cards. It&#39;s crazy that you would pay interest of 23% on what you owe the credit card company. You should pay off your balance there and then retire all your debt… <a href="https://t.co/6O1rIO0pQQ">pic.twitter.com/6O1rIO0pQQ</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1927356996786786449?ref_src=twsrc%5Etfw">May 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
In an interview clip shared with the post, he went further: &#8220;You should pay off your balance there and then retire all your debt and start saving, even if you&#8217;re 30 or 40. You&#8217;d be amazed the <a href="https://www.benzinga.com/general/market-summary/25/05/45490762/charlie-munger-once-said-the-first-rule-of-compounding-is-to-never-interrupt-it-unnecessarily-now-his-wisdom-rings-true-as-the-sp-500-surges-220-over-10-years">power of compounding interest</a> over even a decade. It&#8217;s never too late. The key to life is stay out of debt.&#8221;
O&#8217;Leary also said credit card debt &#8220;comes out of nowhere and bites you&#8221; when you&#8217;re not ready. He called it &#8220;the <a href="https://www.benzinga.com/news/25/02/43424608/21-interest-rates-youve-got-to-be-kidding-me-kevin-oleary-slams-credit-card-debt-as-the-real-silent-killer-in-america">real silent killer</a> in America&#8221; in a separate <a href="https://x.com/kevinolearytv/status/1883537883501310043">interview</a> with WNYW-TV&#8217;s &#8220;Good Day New York,&#8221; emphasizing that most people don&#8217;t even realize how much they&#8217;re overspending.
His advice is to keep it simple: &#8220;Take a piece of paper, you don't need a computer, write down the money you made in 90 days and how much you spent during that same period.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
The reality for many, he says, is that they&#8217;re spending more than they earn. And what makes up the gap? Credit cards, with interest rates now averaging around 21%.
U.S. consumers hold $1.18 trillion in credit card debt in Q1, according to the <a href="https://www.newyorkfed.org/microeconomics/hhdc">Federal Reserve Bank of New York</a>. Balances fell by $29 billion from the previous quarter.
Billionaire Mark Cuban <a href="https://www.benzinga.com/personal-finance/24/05/39092288/if-you-use-your-credit-card-you-do-not-want-to-be-rich-warns-mark-cuban-on-the-dave-ramsey-show">shares the same view</a>. &#8220;If you use your credit cards, you do not want to be rich,&#8221; he told Dave Ramsey on &#8220;<a href="https://www.youtube.com/watch?v=KA0IUaoXSew">The Ramsey Show</a>.&#8221; Cuban suggests paying them off and getting rid of them completely. &#8220;If you pay that down you just earned 15 or 20%,&#8221; he said. Ramsey added that 75% of wealthy people make staying out of debt a top priority.&nbsp;
O&#8217;Leary insists it comes down to buying only what you can truly afford. He used his watches as an example: &#8220;This is a priceless Rolex&#8230; probably worth $150,000. Here&#8217;s a $300 Timex. Why do I wear them both? Two different time zones, but also this is a beautiful dial for 300 bucks.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Kevin O'Leary Says 'It's Crazy' To Pay 23% Interest On Credit Card Debt. Here's What He Thinks 'The Key To Life' Is

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 4.59% on an annualized basis producing an average annual return of 15.6%. Currently, Guidewire Software has a market capitalization of $18.05 billion. 
Buying $1000 In GWRE: If an investor had bought $1000 of GWRE stock 10 years ago, it would be worth $4,273.18 today based on a price of $215.24 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748903412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

GWRE

Here's How Much $1000 Invested In Guidewire Software 10 Years Ago Would Be Worth Today

Afya Limited (NASDAQ:<a href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that its board of directors (the "Board"), following the recommendation of the Board's audit committee, recently approved the engagement of KPMG Auditores Independentes Ltda. ("KPMG") to provide independent auditing services for the Company, replacing Ernst &amp; Young Auditores Independentes S/S Ltda., as its independent registered public accounting firm.
KPMG will commence its activities with the review of our quarterly information for the second quarter of 2025.

Management

AFYA

Afya Limited's Board Approves Engagement Of KPMG As New Independent Auditor

Electric vehicle leader Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is continuing to see large declines in deliveries in many territories around the world, with data from Europe <a href="https://www.benzinga.com/markets/eurozone/25/05/45616006/teslas-european-woes-see-no-end-april-sales-crash-49-as-rivals-race-ahead-in-ev-market">looking particularly bad.</a>
What Happened: Items such as <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">tariffs and macroeconomic concerns</a> could hurt Tesla's delivery figures in the U.S. and other parts of the world.
Europe might be the market Tesla is struggling with the most, which comes as other competitors are outperforming it. The Elon Musk-led company also suffered brand damage in 2024 and 2025 due to the CEO's political involvement in several countries&#8217; <a href="https://www.nbcnews.com/tech/elon-musk/elon-musk-boosting-far-right-politics-globe-rcna189505">elections</a>.
A new report shared by <a href="https://electrek.co/2025/06/02/tesla-sales-crash-france-even-with-new-model-y/">Electrek </a>said Tesla's deliveries in France were 721 units in May. This figure was down 67% year-over-year and is the lowest for the country in over three years.
The overall automotive market was down 12% year-over-year for France in May, but companies outside of Tesla saw much better results.
The report on the struggles in France comes as a recent ACEA report said Tesla's European sales were down 49% year-over-year in April.
Read Also: <a href="https://www.benzinga.com/news/25/05/45681831/is-tesla-insurance-losing-money-new-report-says-business-not-sustainable">Is Tesla Insurance Losing Money? New Report Says Business Not Sustainable</a> 
Why It's Important: Musk insisted that Tesla has "no demand problem" and everything is going fine. Recent delivery reports for regions around the world suggest otherwise and could put second-quarter deliveries in the spotlight.
Tesla placed a portion of its weaker sales blame on the Model Y changeover. May sales for Tesla in France were lower than any month in the first quarter, when the Model Y changeover was happening. With the changeover now complete in some parts of the world, weak second-quarter data shows that this may not have been the reason for weaker demand.
While France represents only one market for Tesla, the May data is bad and could be another negative for second-quarter deliveries and financial results.
TSLA Price Action: Tesla stock closed Monday down 1.09% to $342.69 versus a 52-week trading range of $167.42 to $488.54. Tesla stock is down around 15% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
Photo: Shutterstock

Eurozone

TSLA

Tesla Sales Hit 3-Year Low In This European Nation Despite Musk's Claims Of 'No Demand Problem'

<a href="https://truthsocial.com/@realDonaldTrump/114616038217949758">https://truthsocial.com/@realDonaldTrump/114616038217949758</a>

General

President Trump Posts On Truth Social "The AUTOPEN should have stopped Iran a long time ago from "enriching." Under our potential Agreement — WE WILL NOT ALLOW ANY ENRICHMENT OF URANIUM!"

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 15 years by 2.29% on an annualized basis producing an average annual return of 14.41%. Currently, Masimo has a market capitalization of $8.92 billion. 
Buying $100 In MASI: If an investor had bought $100 of MASI stock 15 years ago, it would be worth $779.18 today based on a price of $165.03 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748902514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MASI

Here's How Much $100 Invested In Masimo 15 Years Ago Would Be Worth Today

Biotech

KURA

Kura Oncology And Kyowa Kirin Announce Phase 2 KOMET-001 Trial Results For Once-Daily Oral Menin Inhibitor Ziftomenib In Relapsed/Refractory NPM1-Mutated AML Showing 23% CR/CRh Rate, Durable MRD-Negative Responses Across Key Subgroups, Favorable Safety With Limited Myelosuppression At ASCO 2025

Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.5, along with a high estimate of $20.00 and a low estimate of $16.00. This current average represents a 14.63% decrease from the previous average price target of $21.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1748901676_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Couchbase among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Announces</td>
<td>Buy</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Couchbase. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Couchbase compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Couchbase's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Couchbase's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BASE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Couchbase analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Couchbase</h2>
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
<h3>Couchbase: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Couchbase's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.65% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -28.42%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Couchbase's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -12.27%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Couchbase's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.46%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Couchbase adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BASE

Where Couchbase Stands With Analysts

Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) underwent analysis by 48 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">14</td>
<td align="right">25</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">17</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $268.15, a high estimate of $320.00, and a low estimate of $190.00. This current average has increased by 11.63% from the previous average price target of $240.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1748901654_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Zscaler. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$305.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$280.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$320.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$295.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Peter Levine</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$295.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$292.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$304.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$310.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$310.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Taz Koujalgi</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Neutral</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$242.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$233.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zscaler. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zscaler compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Zscaler's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Zscaler's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zscaler analyst ratings.</a>
<h2>Unveiling the Story Behind Zscaler</h2>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
<h3>A Deep Dive into Zscaler's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Zscaler's remarkable performance in 3M is evident. As of 30 April, 2025, the company achieved an impressive revenue growth rate of 22.57%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Zscaler's net margin is impressive, surpassing industry averages. With a net margin of -0.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.24%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.08%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Zscaler's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.68.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

48 Analysts Have This To Say About Zscaler

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $382.0, a high estimate of $414.00, and a low estimate of $351.00. This upward trend is evident, with the current average reflecting a 12.19% increase from the previous average price target of $340.50.
<img src="https://www.benzinga.com/files/images/story/2025/1748901618_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Molina Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$351.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$362.00</td>
<td>$339.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$414.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$372.00</td>
<td>$295.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Molina Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Molina Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.24% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Molina Healthcare's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.67%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.77%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Molina Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Molina Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.87.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Molina Healthcare Stock

In the current session, the stock is trading at $136.24, after a 10.70% spike. Over the past month, Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) stock increased by 3.46%, and in the past year, by 6.66%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748901617_0.png" alt="Past Year Chart" />

<h3>Evaluating Steel Dynamics P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Steel Dynamics has a lower P/E than the aggregate P/E of 31.0 of the Metals &amp; Mining industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748901617_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

STLD

Price Over Earnings Overview: Steel Dynamics

Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) has outperformed the market over the past 20 years by 2.79% on an annualized basis producing an average annual return of 11.08%. Currently, Ecolab has a market capitalization of $75.21 billion. 
Buying $1000 In ECL: If an investor had bought $1000 of ECL stock 20 years ago, it would be worth $8,160.97 today based on a price of $265.15 for ECL at the time of writing.
<h3>Ecolab's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748901615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Ecolab 20 Years Ago Would Be Worth Today

<a href="https://www.bloomberg.com/news/articles/2025-06-02/microsoft-layoffs-continue-with-hundreds-more-cut?srnd=homepage-americas&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-02/microsoft-layoffs-continue-with-hundreds-more-cut?srnd=homepage-americas&amp;embedded-checkout=true</a>

MSFT

'Microsoft Cuts Hundreds More Jobs After Firing 6,000 Last Month'- Bloomberg

Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) revealed in an SEC filing Monday that Pierre-Dimitri Gore-Coty, senior vice president of delivery and one of its longest-serving executives, is <a href="https://www.benzinga.com/news/topics/25/06/45714095/chamath-palihapitiya-calls-tesla-an-obvious-win-says-robotaxi-alphabets-waymo-will-overtake-uber-and-lyft">leaving the company.</a>
What To Know: Gore-Coty joined the company in 2012 as general manager in France and later became vice president of mobility for Europe and the Middle East. In 2021, he was appointed senior vice president of delivery, according to <a href="https://www.cnbc.com/2025/06/02/uber-delivery-chief-gore-coty-leaving-almost-13-years-at-company.html">CNBC.</a> 
Read Next: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45727360/amazon-analyst-sees-robotics-unlocking-billions-in-savings?utm_source=articleShare">Amazon Analyst Sees Robotics Unlocking Billions In Savings</a>
CEO Dara Khosrowshahi praised Gore-Coty's contributions in a statement included in the regulatory filing, calling him a "driving force" in the company's global expansion. Gore-Coty helped steer the Uber Eats business through the COVID-19 pandemic.
&#8220;These last nearly 13 years have been the ride of a lifetime," Gore-Coty said in the statement. 
"It was a true team effort, and I'm so proud of what we've built and the impact we've had on daily life in cities around the world,&#8221; he added. 
The company did not disclose his next steps.
What Else: Uber also announced Andrew Macdonald, currently senior vice president of mobility and business operations, will be promoted to chief operating officer.
Macdonald, who joined Uber in May 2012, will oversee global mobility, delivery, autonomous operations and cross-platform teams.
Why It Matters: Uber's stock <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45680442/whats-going-on-with-uber-stock-today-2">fell last week </a>on investor concerns that Tesla, Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) advancements in autonomous ride-hailing could undermine Uber's long-term position, particularly as Tesla's robotaxi model aims to remove human drivers from the equation.
While Uber continues to leverage third-party autonomous vehicle platforms as a cost-efficient provider, Tesla's vertically integrated approach and rapid push toward full autonomy intensify competitive pressure across the sector.
Tesla plans to officially launch its robotaxi program on June 12, starting with 10 to 20 Model Y vehicles equipped with the latest Full Self-Driving (FSD) software. 
Read Next:<a href="https://www.benzinga.com/news/management/25/05/45675714/can-michael-burrys-nvidia-short-survive-the-stocks-stunning-comeback?utm_source=articleShare">&nbsp;</a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/management/25/05/45675714/can-michael-burrys-nvidia-short-survive-the-stocks-stunning-comeback?utm_source=articleShare">Can Michael Burry&#8217;s Nvidia Short Survive The Stock&#8217;s Stunning Comeback?</a></li>
</ul>
Photo: Shutterstock

Movers

Tech

UBER

Uber Reveals Vice President Of Delivery Is Leaving After 'The Ride Of A Lifetime'

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has outperformed the market over the past 5 years by 4.42% on an annualized basis producing an average annual return of 17.58%. Currently, Uber Technologies has a market capitalization of $175.24 billion. 
Buying $1000 In UBER: If an investor had bought $1000 of UBER stock 5 years ago, it would be worth $2,295.91 today based on a price of $83.80 for UBER at the time of writing.
<h3>Uber Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748900719_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Uber Technologies 5 Years Ago Would Be Worth Today

Guidance

Parsons Corp Removes Confidential Contract From 2025 Guidance; Lowers FY25 Total Revenue Guidance To $6.45B-$6.65B; FY25 Revenue Excluding Confidential Contract Guidance $6.165B-$6.365B; Lowers FY25 Adj EBITDA Guidance To $590M-$630M

Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) has outperformed the market over the past 5 years by 7.43% on an annualized basis producing an average annual return of 20.59%. Currently, Axis Capital Holdings has a market capitalization of $8.23 billion. 
Buying $100 In AXS: If an investor had bought $100 of AXS stock 5 years ago, it would be worth $261.75 today based on a price of $104.70 for AXS at the time of writing.
<h3>Axis Capital Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748899826_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Axis Capital Holdings 5 Years Ago Would Be Worth This Much Today

Bridgford Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRID#NASDAQ">BRID</a>) reported quarterly losses of $(0.43) per share. This is a 79.17 percent decrease over losses of $(0.24) per share from the same period last year. The company reported $50.64 million in sales this quarter. This is a 7.03 percent increase over sales of $47.31 million the same period last year.

Earnings

BRID

Bridgford Foods Q2 EPS $(0.43) Down From $(0.24) YoY, Sales $50.64M Up From $47.31M YoY

CUBI

Customers Bancorp Executive Vice President, Chief Financial Officer Philip Watkins To Transition To EVP, Head Of Corporate Development; Mark McCollom Appointed EVP, CFO Effective On Or Around August 15,2025

Northern Dynasty Minerals Received Payment Of $12M Representing The Third Tranche Investment Under The Co's Royalty Agreement Dated July 26, 2022

Press Releases

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Comments

Takeda Pharmaceutical Co

ニュース

最新ニュース Takeda Pharmaceutical Co (NYSE:TAK) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル